# **Data Changes for the CCDD APRIL Release Candidate 2024**

## **Based on the QA Release Generation** 2024-04-02

|  |  |
| --- | --- |
| Data entered by | Jo-Anne Hutsul |
| Data checked by | Anjana Raghuveer |

## **TM File**

### **Deprecation**

The following TM concept(s) needs to be added back into the TM File with a status of **deprecated**. [Reason for deprecation].

|  |  |  |
| --- | --- | --- |
| **tm\_code** | **tm \_formal\_name** | **tm\_status** |
|  | [NONE] |  |

### **Code permanence – name changes**

The following TM concept(s) need to keep its/their existing tm\_code even though their formal name has changed. [Reason for name change].

|  |  |  |
| --- | --- | --- |
| **tm\_code (to keep)** | **tm \_formal\_name** | **tm\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence - returns**

The following TM concept(s) is/are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate with a status of “inactive”, when its/their supporting NTPs and MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **tm\_code** | **tm \_formal\_name** |
| 8002430 | SARS-CoV-2 recombinant spike protein |

## **NTP File**

### **Deprecation**

The following NTP concept(s) needs to be added back into the NTP File with status of **deprecated**.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
| 9014842 | ranibizumab 2.3 mg per 0.23 mL solution for injection vial | ranibizumab 2,3 mg par 0,23 mL solution injectable fiole | Deprec |
| 9000005 | epinephrine (epinephrine hydrochloride) 30 mg per 30 mL solution for injection ampoule | épinéphrine (chlorhydrate d'épinéphrine) 30 mg par 30 mL solution injectable ampoule | Deprec |

### **Status update – Inactive**

The following NTP concept(s) are generating as Active but need to be set to **inactive** to align with their respective MPs.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
|  | [NONE] |  | Inactive |

### **Code permanence – name changes**

The following NTP concepts need to keep their existing ntp\_code even though their formal name has changed.

|  |  |  |
| --- | --- | --- |
| **ntp\_code (to keep)** | **ntp \_formal\_name** | **ntp\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence – returns check**

The following NTP concepts are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate, when their supporting MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **ntp\_code** | **ntp \_formal\_name** |
| 9004609 | darunavir 75 mg oral tablet |
| 9014736 | desmopressin (desmopressin acetate) 50 mcg sublingual tablet |
| 9013959 | enasidenib (enasidenib mesylate) 50 mg oral tablet |
| 9013575 | lixisenatide 20 mcg per actuation solution for injection pre-filled pen |
| 9013328 | ropivacaine hydrochloride 100 mg per 10 mL solution for injection vial |
| 9013333 | ropivacaine hydrochloride 200 mg per 20 mL solution for injection vial |
| 9014747 | SARS-CoV-2 recombinant spike protein 5 mcg per 0.5 mL suspension for injection 5 mL vial |
| 9013528 | triamcinolone hexacetonide 20 mg per 1 mL suspension for injection ampoule |

## **MP File**

### **Deprecation (very rare)**

No new deprecated concepts.

### **Deprecation – manual return**

The following MP concepts need to be added back into the MP File with status of **deprecated**. The product has been transferred from DPD to LNHPD.

|  |  |  |  |
| --- | --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_fr\_description** | **mp\_status** |
|  | [NONE] |  | Deprec |

### **Status update – deprecation**

The following MP concepts are generating as active but need to be set to **deprecated**. Some of these products have been assigned a new DIN, others have been discontinued.

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
|  | [NONE] | Deprec |

### **Status update – Inactive**

The following MP concepts are generating as active but need to be set to **inactivated**. The DIN is still active but these particular presentations have been discontinued.

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
|  | [NONE] | Inactive |

### **DPD descriptors**

The following concept(s) needs to have the DPD descriptor added to the brand name to allow differentiation between duplicate mp\_formal names.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_  code | mp\_code | mp\_formal\_name | DPD descriptor | DPD descriptor - FR |
|  | [NONE] |  |  |  |

### **Concept permanence – manual return**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_code | mp\_code | mp\_formal\_name | mp\_fr\_description | CCDD status |
|  | [NONE] |  |  |  |

### **Code permanence – name changes**

The following MP concept(s) need to keep its/their existing mp\_code even though their formal name has changed. [Reason for name change].

|  |  |  |
| --- | --- | --- |
| **mp\_code (to keep)** | **mp \_formal\_name** | **mp\_code in QA Release was** |
| 77700212 | ADRENALIN (epinephrine (epinephrine hydrochloride) 30 mg per 30 mL solution for injection vial) SEARCHLIGHT PHARMA INC | 8fb97fe635b9b2f4f9b34481bee665b6 |

### **Concept permanence – returns check**

The following MPs need to be added to the Inclusion list to make sure that they (and their associated NTPs/TMs) continue to be present in the release:

|  |  |  |  |
| --- | --- | --- | --- |
| **drug\_code** | **mp\_code** | **mp\_formal\_name** | **DPD status** |
| 78282 | 2297477 | ACT AMLODIPINE (amlodipine (amlodipine besylate) 2.5 mg oral tablet) TEVA CANADA LIMITED | Dormant 2024.03.19 |
| 95244 | 2464284 | ADLYXINE (lixisenatide 20 mcg per actuation solution for injection pre-filled pen) SANOFI-AVENTIS CANADA INC | Cancelled post-market Expiry 2024.03.31 |
| 83852 | 2353326 | CIPROFLOXACIN (ciprofloxacin (ciprofloxacin hydrochloride) 500 mg oral tablet) SANIS HEALTH INC | Dormant 2024.03.28 |
| 98762 | 2497824 | DOVE DERMA + CARE SCALP ANTI-DANDRUFF DRYNESS & ITCH RELIEF 2 IN 1 (pyrithione zinc 1 % shampoo) UNILEVER CANADA | Cancelled post-market Expiry 2023.09.16 |
| 19648 | 2190885 | GLUCOBAY (acarbose 50 mg oral tablet) BAYER INC | Cancelled post-market Expiry 2024.03.31 |
| 97567 | 2485427 | IDHIFA (enasidenib (enasidenib mesylate) 50 mg oral tablet) CELGENE INC | Cancelled post-market Expiry 2024.03.31 |
| 19716 | 2190915 | LOSEC (omeprazole (omeprazole magnesium) 20 mg gastro-resistant tablet) CHEPLAPHARM ARZNEIMITTEL GMBH | Cancelled post-market Expiry 2024.03.31 |
| 83599 | 2350785 | NAPROXEN EC (naproxen 250 mg gastro-resistant tablet) SANIS HEALTH INC | Cancelled post-market Expiry 2024.03.31 |
| 83600 | 2350793 | NAPROXEN EC (naproxen 375 mg gastro-resistant tablet) SANIS HEALTH INC | Cancelled post-market Expiry 2024.03.31 |
| 91551 | 2431076 | NOCDURNA (desmopressin (desmopressin acetate) 50 mcg sublingual tablet) FERRING INC | Cancelled post-market Expiry 2024.03.31 |
| 101438 | 2525364 | NUVAXOVID (SARS-CoV-2 recombinant spike protein 5 mcg per 0.5 mL suspension for injection 5 mL vial) NOVAVAX INC. | Cancelled post-market Expiry 2024.02.29 |
| 82408 | 2338432 | PREZISTA (darunavir (darunavir ethanolate) 75 mg oral tablet) JANSSEN INC | Cancelled post-market Expiry 2024.02.29 |
| 100265 | 77701075 | RIABNI (rituximab 100 mg per 10 mL solution for injection vial) AMGEN CANADA INC | Dormant 2023.12.03 |
| 100265 | 77701076 | RIABNI (rituximab 500 mg per 50 mL solution for injection vial) AMGEN CANADA INC | Dormant 2023.12.03 |
| 85541 | 2370255 | RISEDRONATE (risedronate sodium (risedronate sodium monohydrate) 35 mg oral tablet) SANIS HEALTH INC | Dormant 2024.03.15 |
| 97274 | 2482274 | RIVA-LEVETIRACETAM (levetiracetam 250 mg oral tablet) LABORATOIRE RIVA INC. | Dormant 2024.01.02 |
| 97275 | 2482282 | RIVA-LEVETIRACETAM (levetiracetam 500 mg oral tablet) LABORATOIRE RIVA INC. | Dormant 2024.01.02 |
| 97276 | 2482290 | RIVA-LEVETIRACETAM (levetiracetam 750 mg oral tablet) LABORATOIRE RIVA INC. | Dormant 2024.01.02 |
| 98271 | 2492725 | RIVA-LEVOFLOXACIN (levofloxacin (levofloxacin hemihydrate) 250 mg oral tablet) LABORATOIRE RIVA INC. | Dormant 2023.01.19 |
| 98272 | 2492733 | RIVA-LEVOFLOXACIN (levofloxacin (levofloxacin hemihydrate) 500 mg oral tablet) LABORATOIRE RIVA INC. | Dormant 2023.01.19 |
| 98273 | 2492741 | RIVA-LEVOFLOXACIN (levofloxacin (levofloxacin hemihydrate) 750 mg oral tablet) LABORATOIRE RIVA INC. | Dormant 2023.01.19 |
| 83320 | 77700877 | ROPIVACAINE HYDROCHLORIDE INJECTION USP (ropivacaine hydrochloride 100 mg per 10 mL solution for injection vial) PFIZER CANADA ULC | Cancelled post-market  Expiry 2024.04.01 |
| 83320 | 77700878 | ROPIVACAINE HYDROCHLORIDE INJECTION USP (ropivacaine hydrochloride 200 mg per 20 mL solution for injection vial) PFIZER CANADA ULC | Cancelled post-market  Expiry 2024.04.01 |
| 77118 | 2285673 | SANDOZ FOLIC ACID (folic acid 5 mg oral tablet) SANDOZ CANADA INCORPORATED | Dormant 2023.03.27 |
| 93048 | 2445247 | SPOT CLEARING LOTION (benzoyl peroxide 2.5 % cutaneous gel) ALUMIER EUROPE LTD | Cancelled post-market  Expiry 2024.03.31 |
| 76496 | 2279355 | STRATTERA (atomoxetine (atomoxetine hydrochloride) 100 mg oral capsule) ELI LILLY CANADA INC | Cancelled post-market  Expiry 2024.03.15 |
| 95963 | 2470632 | TRISPAN (triamcinolone hexacetonide 20 mg per 1 mL suspension for injection ampoule) MEDEXUS PHARMACEUTICALS INC. | Cancelled post-market Expiry 2023.08.31 |
| 84250 | 2357380 | ULORIC (febuxostat 80 mg oral tablet) TAKEDA CANADA INC | Cancelled post-market  Expiry 2024.03.31 |
| 98508 | 2495120 | ZERO HEALTHY GUMS (cetylpyridinium chloride 0.075 % mouthwash) COLGATE-PALMOLIVE CANADA INC | Cancelled post-market  Expiry 2024.03.30 |

## **Exclusion List (on GitHub)**

The following changes have been made to the Exclusion List for the APRIL 2024 Release Candidate. The list as it is on GitHub should be used.

Changes that have been made to the Exclusion List are as follows:  
ACTION is either:

* STAY on Exclusion List
* ADD to Exclusion List
* REMOVE from Exclusion List

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **ntp\_code** | **ntp\_formal\_name** | **drug\_code** | **mp\_code** | **mp\_formal\_name** | **ACTION** |
| 63c8f110ed79d2e861bae01cb8891ce7 | cytarabine 100 mg and daunorubicin 44 mg powder for solution for injection | 100489 | 02515490 | VYXEOS (cytarabine 100 mg and daunorubicin 44 mg powder for solution for injection) JAZZ PHARMACEUTICALS IRELAND LIMITED | STAY |
| 9e3fb80210482640e5444ef81ae1c6a9 | cisplatin 1 mg per mL solution for injection | 102507 | 02536285 | CISPLATIN INJECTION BP (cisplatin 1 mg per mL solution for injection) HIKMA CANADA LIMITED | REMOVE |
| 5337a590b31d246add65ba99b6d94f12 | elranatamab 44 mg per 1.1 mL solution for injection | 103201 | 02543559 | ELREXFIO (elranatamab 44 mg per 1.1 mL solution for injection) PFIZER CANADA ULC | REMOVE |
| 41d14fe928628e909f59b06c220a4842 | elranatamab 76 mg per 1.9 mL solution for injection | 103202 | 02543567 | ELREXFIO (elranatamab 76 mg per 1.9 mL solution for injection) PFIZER CANADA ULC | REMOVE |
| 9cda20aefa820edec57ea9744c742ecf | ranibizumab 10 mg per mL solution for injection | 103083 | 02542250 | RANOPTO (ranibizumab 10 mg per mL solution for injection) TEVA CANADA LIMITED | REMOVE |
| 9014932 | rocuronium bromide 10 mg per mL solution for injection | 101907 | 02529831 | ROCURONIUM BROMIDE INJECTION (rocuronium bromide 10 mg per mL solution for injection) JAMP PHARMA CORPORATION | REMOVE |